ANI Pharmaceuticals opened higher at $71.56, compared with its previous close of $71.09. In the last trading session, the stock traded between $70.00 and $71.56. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in ANI Pharmaceuticals is now worth
$ 156.57
Giving a profit of
$ 56.57 (56.57%)
Note: Past profits do not guarantee future returns.
Rating from 7 Analysts
Today's Change
$-0.13 (-0.19%)
Day High
$71.56
Day Low
$70.00
Day Open
$71.56
Prev Close
$71.09
Volume
2,59,461
1W Return
-0.86%
1M Return
-3.64%
3M Return
-4.76%
6M Return
-9.85%
1Y Return
-19.86%
Market Cap ($ Mn)
1,612
PE Ratio
15.76
PB Ratio
2.80
PEG Ratio
-
ROE
16.99%
ROCE
10.37%
EPS (TTM)
$1.53
1 Week
-0.86%
1 Month
-3.64%
3 Months
-4.76%
6 Months
-9.85%
9 Months
-6.94%
Guggenheim raises ANI Pharmaceuticals price target to $121
Guggenheim maintains a Buy rating on ANI Pharmaceuticals. Price target raised from $119 to $121 by analyst Vamil Divan.
6 days agoANI Pharma cuts Cortrophin guidance, announces $560M Egetis deal
ANI Pharmaceuticals reports Q3FY26 revenue of $290.8M, up 27.6% YoY. Announces $560M acquisition of Egetis Therapeutics to expand rare disease portfolio. Revises FY26 Cortrophin Gel revenue guidance down to $480M-$500M due to pharmacy bottlenecks. Raises FY26 adjusted non-GAAP EPS guidance to $9.37-$9.71, beating consensus estimates. Ends quarter with $420.8M cash; plans to fund Egetis deal with cash and up to $300M debt.
7 days agoANI Pharmaceuticals to present ILUVIEN Phase 4 trial data at AAO 2026
ANI Pharmaceuticals to present ILUVIEN Phase 4 SYNCHRONICITY trial data at AAO 2026. Oral presentation scheduled for October 9, 2026, during Uveitis Subspecialty Day. Post-hoc analyses from NEW DAY trial for DME available as on-demand ePoster. Encore presentation planned for Hawaiian Eye & Retina 2027 Meeting in January 2027.
1mo agoANI Pharmaceuticals to present at three September investor conferences
ANI Pharmaceuticals CEO Nikhil Lalwani will lead fireside chats at three September 2026 investor conferences. Appearances scheduled at Wells Fargo (Sept 10), Morgan Stanley (Sept 14), and H.C. Wainwright (Sept 15). Live and archived webcasts will be accessible via the company’s investor relations website.
2mo agoANI Pharmaceuticals appoints Henry Gosebruch to board of directors
Henry Gosebruch joins ANI Pharmaceuticals board effective August 19, 2026. Appointment focuses on strengthening corporate strategy and M&A capabilities. Samy Shanmugam resigns as director but retains executive management roles. Gosebruch brings over 30 years of biopharma strategy and finance experience.
2mo agoAnalysts cut ANI Pharmaceuticals targets despite Q2 earnings beat
ANI Pharmaceuticals reported Q2 2026 EPS of $2.21 and revenue of $266.044 million, beating consensus estimates. Driven by a 43.5% surge in Cortrophin Gel sales, the company affirmed full-year revenue and EPS guidance. However, shares dropped 3.2% as analysts from Canaccord Genuity and Guggenheim lowered their price targets to $90 and $119 respectively, citing valuation concerns despite operational strength.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $1,437.29 | +0.35% | $13,52,123.38M | 39.43 | |
| $280.41 | -0.13% | $6,75,033.80M | 31.06 | |
| $294.98 | +0.37% | $5,21,411.37M | 72.17 | |
| $147.18 | -0.59% | $3,62,834.91M | 117.74 | |
| $160.32 | -1.80% | $3,26,222.34M | 23.23 | |
| $185.48 | -0.69% | $2,87,691.54M | 24.32 | |
| $468.11 | +0.62% | $2,53,205.85M | 26.86 | |
| $169.73 | -0.67% | $2,10,522.74M | - | |
| $29.45 | +0.31% | $1,67,860.70M | 36.79 | |
| $41.09 | +0.96% | $1,39,300.36M | 11.15 | |
| $62.91 | +0.18% | $1,28,593.45M | 14.67 | |
| $48.43 | +0.41% | $1,16,984.89M | 23.63 |
An investment of $100 made 5 years ago in ANI Pharmaceuticals is now worth
$ 156.57
Giving a profit of
$ 56.57 (56.57%)
Note: Past profits do not guarantee future returns.
